Id1 and Id3 co-expression correlates with clinical outcome in stage III-N2 non-small cell lung cancer patients treated with definitive chemoradiotherapy by Eduardo Castañon et al.
Castañon et al. Journal of Translational Medicine 2013, 11:13
http://www.translational-medicine.com/content/11/1/13RESEARCH Open AccessId1 and Id3 co-expression correlates with clinical
outcome in stage III-N2 non-small cell lung
cancer patients treated with definitive
chemoradiotherapy
Eduardo Castañon1†, Joaquim Bosch-Barrera1†, Inés López2, Víctor Collado2, Marta Moreno3,
José María López-Picazo1, Leire Arbea3, María Dolores Lozano4, Alfonso Calvo2 and Ignacio Gil-Bazo1,2*Background: Inhibitor of DNA binding 1 (Id1) and 3 (Id3) genes have been related with the inhibition of cell
differentiation, cell growth promotion and tumor metastasis. Recently, Id1 has been identified as an independent
prognostic factor in patients with lung adenocarcinoma, regardless of the stage. Furthermore, Id1 may confer
resistance to treatment (both, radiotherapy and chemotherapy).
Methods: We have studied, using monoclonal antibodies for immunohistochemistry, the Id1 and Id3 tumor
epithelial expression in 17 patients with stage III-N2 non-small cell lung cancer (NSCLC) treated with definitive
chemoradiotherapy.
Results: Id1 expression is observed in 82.4% of the tumors, whereas Id3 expression is present in 41.2% of the samples.
Interestingly, Id1 and Id3 expression are mutually correlated (R = 0.579, p = 0.015). In a subgroup analysis of patients
with the most locally advanced disease (T4N2 stage), co-expression of Id1 and Id3 showed to be related with a worse
overall survival (45 vs 6 months, p = 0.002). A trend towards significance for a worse progression free survival (30 vs
1 months, p = 0.219) and a lower response rate to the treatment (RR = 50% vs 87.5%, p = 0.07) were also observed.
Conclusions: A correlation between Id1 and Id3 protein expression is observed. Id1 and Id3 co-expression seems associated
with a poor clinical outcome in patients with locally advanced NSCLC treated with definitive chemoradiotherapy.
Keywords: Non-small cell lung cancer, Chemoradiotherapy, Id1, Id3, Protein expression, PrognosisBackground
Lung cancer represents the first cause of cancer death
among men and women in the USA and Europe. Locally
advanced stage III disease accounts for 25–30% of all cases
of non-small cell lung cancer (NSCLC) at onset [1]. For
patients with unresectable or inoperable stage III disease,
the combination of platinum-based chemotherapy and
radiotherapy has been considered the standard treatment
with a 5-year survival rate of 20-30% in different studies
[2,3]. Recently, we have communicated our experience in* Correspondence: igbazo@unav.es
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reproduction in any medium, provided the orthe treatment of stage III-N2 NSCLC disease, with a 5-
year survival rate of 23% and a median overall survival of
41 months for patients treated with definitive concurrent
chemoradiotherapy [4]. The poor clinical outcome in this
subset of NSCLC patients urges the identification of spe-
cific biomarkers able to predict survival, as a priority goal
in lung cancer translational research. The availability
of those prognostic and predictive factors may help to
identify patients who would most likely benefit from the
different treatment modalities available [5]. Furthermore,
the characterization of novel potential molecular targets
may aid to design new personalized therapies in the differ-
ent subgroups of patients identified.
The Inhibitor of DNA binding/Inhibitor of differenti-
ation (Id) family members are part of the helix-loop-
helix proteins lacking a basic DNA binding domain [6].al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Id2, Id3, and Id4. The Id genes have been suggested to
be oncofetal genes that are expressed in embryos or
fetuses, downregulated or undetectable in adult tissues,
and re-expressed in tumors. They play a crucial role dur-
ing embryogenesis [7], but they have been also related
with cancer [8]. Thus, Id proteins can contribute to
tumorigenesis by inhibiting cell differentiation, stimulat-
ing proliferation and facilitating tumor neoangiogenesis
[8]. Moreover, Id1 has been shown to mediate chemo-
therapy resistance in hormone-independent prostate
cancer cells [9,10] and ERK activation, and JNK and
p38MAPK inhibition by Id1 in those cells has been sug-
gested to be responsible for that resistance [9,10].
The prognostic role of the expression of Id family pro-
teins in lung cancer was initially explored in small-cell
lung cancer [11]. More recently, our group has studied the
expression of Id1 in a large series including more than
four hundred NSCLC patients. We described that Id1 ex-
pression was a poor prognostic marker for lung adenocar-
cinoma [12]. Thus, in radically treated stages I to III
patients and stage IV patients treated with chemotherapy,
higher Id1 levels were associated with a shorter disease-
free survival and overall survival in adenocarcinoma
patients. Moreover, a Cox model confirmed the independ-
ent prognostic value of Id1 levels for these patients. More
interestingly, we showed that Id1 downregulation in pri-
mary treatment-resistant adenocarcinoma cell lines sensi-
tizes those cells to radiotherapy and chemotherapy
treatment in vitro [12], although no mechanistic experi-
ments where performed to explain that observation. In
other neoplasms, such as prostate cancer, the overexpres-
sion of Id1 has been also related to radioresistance [13].
Id1 and Id3 are considered to have overlapping and
synergistic functions in cancer biology and have been
related with the inhibition of cell differentiation, cell
growth promotion and tumor metastasis [14]. To our
knowledge, the Id3 protein expression in human NSCLC
has never been explored, nor its correlation with Id1 ex-
pression or its predictive value.
In the present manuscript, we have studied the poten-
tial prognostic and predictive role of Id1 and Id3 expres-
sion by immunohistochemistry in stage III-N2 patients
treated with definitive chemoradiotherapy.
Methods
Patients’ characteristics and tissue samples
We explored a cohort of 34 patients with stage III-N2
NSCLC disease treated, as previously published [4], with
definitive concurrent chemoradiotherapy and followed at
the Clínica Universidad de Navarra (CUN) between
1996 and 2006.
These patients were radically treated with induction
platinum-based chemotherapy, followed by concurrentchemotherapy and hyperfractioned 3D-CRT [1.2 Gy b.i.d.;
median dose: 66.5 Gy (range: 64–74)]. Paclitaxel (50 mg/
m2) and cisplatin (30 mg/m2) were administered intraven-
ously over a 60-min period on days 1, 8, 15, 22, 29 and 36
after confirmation of adequate blood cells counts.
From the whole cohort, tumor tissue samples were
available and evaluable by immunohistochemistry for
Id1 and Id3 expression in 17 patients. In 15 of the cases,
samples represented primary tumor tissues and in
remaining 2, lymph node biopsies were included assum-
ing a homogeneous Id1 and Id3 expression between pri-
mary and lymph node samples. Of these 17 patients
70.6% were male; the median age of the cohort was
54 years (range, 41–78 years); 76.5% of the tumors
showed squamous cell histology, 11.8% showed adeno-
carcinoma and 11.7% were NSCLC not otherwise speci-
fied (NOS). The study protocol was approved by the
ethical committee of our institution.
Immunohistochemical analysis
Id1 and Id3 expression was evaluated using indirect
immunoperoxidase staining of formalin-fixed paraffin-em-
bedded tissue sections (9 samples) as well as cell block sec-
tions (2 samples), as described previously [15]. The rabbit
monoclonal anti-mouse/human Id1 (L/N: RN-42730) and
Id3 (L/N: RN-38144) antibodies (1:100; Biocheck, CA,
USA) were used. Detection was conducted with the
AdvanceTM HRP system (Dako, Glostrup, Denmark).
In addition, alcohol-fixed cytology slides from fine-
needle biopsies were the only tumor material available
in six patients, and they were processed as previously
described [16]. Briefly, each sample was exposed to 100%
acetone for 5 min using an individual coupler per sample,
to facilitate coverglass removal. During the next 5 min,
samples were washed with 100% acetone and dried, After,
washing samples with 100% ethanol for 3 minutes, en-
dogenous peroxidase activity was blocked by incubation in
3% hydrogen peroxide in methanol for 30 min in a dark
room, and then the samples were rinsed with 100% etha-
nol for 3 minutes followed by sequential washes in de-
creasing concentrations of ethanol. After this point,
samples followed the standard protocol for biopsy tissues.
Staining scores were determined by a semiquantitative
analysis (H-score) as previously described [17]. Briefly,
the extension and intensity of the staining was evaluated
by two observers, independently and blinded for any
clinical data. The extension was scored as a percentage
of positive cells (0 = 0%, 1 = 1-5%, 2 = 5-50% and 3 = 50-
100%) and the intensity of staining was assessed com-
pared with a known external positive control (0 = no
staining, 1 = weak, 2 = moderate, and 3 = strong stain-
ing). A final H-score was calculated using the products
of the percentage of cells stained at a given staining in-
tensity (0–3) and the staining intensity (0–3). The
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Staining of vascular endothelial cells for Id1 and Id3
served as an internal control for immunohistochemistry
when possible (tumor biopsies) as previously published
[12]. In immunostaining analysis with cell blocks and
tumor cytology smears, samples were run together with
known positive samples used as positive controls.
Statistical analysis
The correlation between Id1 and Id3 H-score was evalu-
ated by the Spearman’s rank correlation coefficient. This
non parametric test was also applied to analyze the rela-
tion between the product of Id1 and Id3 H-score and the
overall survival (OS) and progression-free survival (PFS).
The relation between Id1 and Id3 expression and the re-
sponse rate was also studied by using the MacNemar’s
test. Kaplan–Meier survival curves were generated to
evaluate the PFS and OS. A log-rank test was performed
to find statistical differences in the Kaplan–Meier survival
analyses. Statistical significance was defined as p-values <
0.05. The SPSS 15.0 software (SPSS, Inc., Chicago, IL) was
employed to perform the statistical analysis.
Results
Expression of Id1 and Id3 in NSCLC tissue by
immunohistochemistry
Tumor samples from 17 patients out of the 34 NSCLC
patients treated with definitive chemoradiotherapy were
available. Clinical characteristics of the 17 patients ana-
lyzed are summarized in table 1. The tumor epithelial ex-
pression and H-score of Id1 and Id3 of these patients is
detailed in table 2. Id1 expression was observed in 82.4%
of the patients, whereas Id3 expression was present in the
41.2% of the patients (figure 1). All patients that presented
Id3 expression had also Id1 expression. We were able to
identify Id1 and Id3 epithelial expression in all kinds of
samples available (biopsy, cell block, and cytology).
Prognostic value of Id1 and Id3 expression
We investigated whether the expression of Id1 and Id3
in stage III-N2 NSCLC patients treated with definitive
chemoradiotherapy could serve as a prognostic bio-
marker. First, we observed that the expression of Id1
and Id3 were significantly correlated in a positive trend
(R = 0.579, p = 0.015), (figure 1, A and B; figure 2).
For this reason and considering the well-known syner-
gies between both Id genes, we hypothesized that the
product of the H-score of Id1 and Id3 (Id1/Id3) could bet-
ter correlate with the clinical outcomes to the treatment
in the specific subgroup of patients with more advanced
stage (cT4N2 disease) treated with definitive concurrent
chemoradiotherapy (n = 9).
Firstly, the response rate (RR) achieved with the treat-
ment seemed to be lower among patients showing a tumorId1/Id3 co-expression compared to those showing no Id1/
1d3 co-expression with a trend towards statistical signifi-
cance using the MacNemar’s test, (RR = 50% vs 87.5%, re-
spectively; p = 0.07). Accordingly, a significant correlation
between Id1/Id3 co-expression and the OS (R = −0.733,
p = 0.025) was observed. The correlation between Id1/Id3
co-expression and the PFS also showed a trend towards
the statistical significance (R = −0.639, p = 0.064).
These results were confirmed by the Kaplan-Meier
curves and log-rank test. A significantly worse prognosis in
terms of OS for patients that presented co-expression of
Id1/Id3 in their tumor samples compared to those with a
complete lack of Id1/Id3 co-expression (45 months vs
6 months; p = 0.002), was observed, as showed in figure 3.
PFS also showed differences in favor of patients showing no
Id1/Id3 tumor co-expression although a statistical signifi-
cance was not achieved (30 months vs 1 month, p = 0.219),
(figure 3). However, for those patients with tumor samples
showing an exclusive Id1 expression in the absence of Id3
expression, no impact of that expression on clinical out-
comes was observed. In fact, the OS for patients with
Id1-expressing tumors was 45 months compared to
41 months in subjects with tumors showing no Id1 expres-
sion, p = 0.646. Similar results were obtained for PFS
(94 months versus 11 months respectively, p = 0.588).
Finally, no correlation between the exclusive expression
of Id3 in the absence of Id1 expression with clinical out-
comes could be studied because in our series, all patients
with Id3-expressing tumors concurrently showed Id1 ex-
pression, as shown in table 2.
Discussion
In a previous study, we showed that a high Id1 protein
expression is an independent prognostic biomarker in
patients with adenocarcinoma of the lung, regardless the
stage [12]. Also, we observed that Id1 silencing may
Table 2 Pattern of expression of Id1 and Id3 proteins in the 17 evaluable patients
Patient
number
Tissue Staining intensity Percentage of staining H-score
Id1 Id3 Id1 Id3 Id1 Id3
10 LB 1 0 2 0 2 0
2 BB 2 1 3 1 6 1
3 BB 2 2 1 1 2 2
5 BB 1 1 1 1 1 1
6 BB 1 1 2 1 2 1
7 BB 2 1 2 2 4 2
8 BB 1 0 3 0 3 0
1 LNB 3 3 3 2 9 6
11 LNB 0 0 0 0 0 0
4 CB 0 0 0 0 0 0
9 CB 1 0 2 0 2 0
12 C 0 0 0 0 0 0
13 C 1 0 2 0 2 0
14 C 0 0 0 0 0 0
15 C 1 0 2 0 2 0
16 C 1 0 1 0 1 0
17 C 1 1 2 1 2 1
Tissue sample: LB (lung biopsy), BB (bronchial biopsy), LNB (lymph node biopsy), CB (cell block sample), C (cytology sample). Staining intensity (0: no staining, 1:
weak, 2: moderate, 3: strong staining). Percentage of staining (0 = 0%, 1 = 0-5%, 2 = 5-50%, 3 > 50%).
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chemotherapy [12].
In the present study we tried to validate the previous
in vitro observations in a clinical series of NSCLC
patients receiving chemoradiotherapy with radical intent.
Despite some limitations regarding its retrospective na-
ture and the relatively short cohort studied, we find forFigure 1 Id1 and Id3 immunohistochemistry in non-small cell lung ca
expression (20×) with final H-score of 6 (B). Lack of Id1 (20×) (C) and Id3 (2the first time that the co-expression of Id1 and Id3 in
the tumor epithelium can be a powerful prognostic bio-
marker in a selected subgroup of stage III-N2 NSCLC
patients receiving definitive chemoradiotherapy.
In several studies with neuroblastoma cell lines, Id
genes have been shown to be overexpressed by tumor
hypoxia [18,19]. On the other hand, in several tumorncer samples. Id1 expression (20×) with final H-score of 9 (A) and Id3
0×) (D) expression with final H-score of 0.
Figure 2 Spearman’s rank correlation curve between Id1 and Id3 in all patients with tumor sample available for the study (n = 17).
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key factor in the induction of radioresistance [20,21].
Thus, it seems biologically plausible that higher Id1 and
Id3 tumor expression levels may reflect the hypoxic status
of the neoplasm and therefore would explain the radiore-
sistance observed in those patients. In fact, elevated Id1Figure 3 Kaplan-Meier curves for Progression-Free Survival (PFS) (A) a
Id3 co-expression.and Id3 protein levels have been found in vitro and by
immunohistochemistry in samples of many different
human carcinoma types supporting the role of both genes
in carcinogenesis [8].
The correlation between Id1 and Id3 and its functional
implications have been studied in other cancers. Fornd Overall Survival (OS) (B) of T4N2 patients with or without Id1/
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metastasize in Id1 (+/−) Id3 (−/−) knockout mice [22]. In
addition, when Id1 and Id3 are both interfered by Id1/3-
PA7, an antiproliferative and apoptotic effect can be
observed in breast cancer cells [22]. Similarly, the com-
bined inhibition of Id1 and Id3 in human pancreatic
tumor cells resulted in decreased ability of pancreatic can-
cer cells to proliferate and migrate. In addition, Id1/Id3
double-knockdown caused decreased expression of integ-
rins alpha3, alpha6, and beta1, and consequently reduced
adhesion of tumor cells to laminin. Finally, peritoneal me-
tastases of Id1/Id3 double-knockdown tumor cells were
significantly reduced in a mouse model of peritoneal me-
tastasis [23]. Moreover, functional studies have shown that
Id1 and Id3 are required for both, tumor initiation and
during metastatic colonization of the lung microenviron-
ment by breast cancer cells [24]. Recently, Id1 and Id3 co-
expression (but not its individual expression) has been
proposed as a novel mechanism of regulation of the self-
renewal capacity of human colon cancer-initiating cells
(CC-ICs) [25]. In that study, regulation of p21 exerted by
Id1 and Id3 seemed to be a central mechanism preventing
the accumulation of excess DNA damage and subsequent
functional exhaustion of CC-ICs. Remarkably, the Id1 and
Id3 co-silencing in LS174T colon cancer cells in the same
study, was able to increase the sensitivity of colon cancer-
initiating cells to oxaliplatin, linking tumor initiation with
chemotherapy resistance and underlying the potentially
synergistic properties between Id1 and Id3 [25]. Further-
more, in a study by Perry et al., Id1 seemed to have a role
in long-term repopulating hematopoietic stem-cell main-
tenance and hematopoietic development, and more inter-
estingly, it was able to functionally compensate the Id3
loss presumably due to its similar biological properties
[26]. All these evidences seem to indicate that although
Id1 and Id3 may show some similar and redundant bio-
logical properties during embryonic development and
tumorigenesis, their differential regulation could explain
their complementary and ultimately distinct functions, as
demonstrated in the postmitotic Sertoli cell [27].
With regard to NSCLC, other authors have also
observed that Id1 is expressed in a nuclear pattern in
the majority of squamous cell carcinomas (70%) and
non-squamous cell carcinomas (50%) of the lung [17].
However, the expression and potential role of Id3 and its
correlation with Id1 expression have not been previously
studied in NSCLC patients.
In the present study, also for the first time, tumor cell
blocks and cytology smears have been included for Id1
and Id3 immunostaining analysis. This approach repre-
sents a challenge but could also implicate a potential
methodological caveat due to the small quantity of tissue
that may underestimate the expression of both proteins.
However, in the last several years, especially in the fieldof lung cancer, immunocytochemestry has gained im-
portance in better characterizing samples with diagnostic
and prognostic purposes showing a reliable performance
for most of the antibodies used [28].
Although the expression of Id1 and Id3 were mutually
correlated in a positive trend in our series, a remarkably
higher (and more frequent) expression of Id1 compared to
Id3 was observed in the NSCLC samples analyzed. This
represents a novel finding since no other study has previ-
ously investigated the expression of both proteins in the
same NSCLC samples. Whether this more intense and
abundant Id1 expression among NSCLC samples, com-
pared to Id3 expression, is able to functionally compensate
a lower expression of Id3 warrants a further in vitro and
in vivo investigation. More interestingly, the co-expression
of both proteins Id1 and Id3, in the same tumor samples,
showed a significant inverse correlation with OS in those
patients showing a clinical stage considered of worse prog-
nosis (cT4N2 disease). Those results were also corrobo-
rated by the Kaplan-Meier and log-rank tests showing a
significantly worse prognosis in terms of OS for patients
that presented co-expression of Id1/Id3 in their tumor
samples compared to those with a complete lack of Id1/
Id3 co-expression (45 months vs 6 months; p = 0.002).
Additionally, the PFS analysis showed similar differences
in favor of patients lacking Id1/Id3 co-expression in their
tumor samples, although the limited number of patients
included could have accounted for the lack of statistical
significance observed. Finally and according to our previ-
ous results in vitro, the response rate associated with the
chemoradiotherapy administered to the patients was a
37.5% lower among those subjects with tumors showing a
co-expression of Id1 and Id3. However, this observation
only showed a trend towards significance probably due to
insufficient statistical power.
An isolated Id1 expression had no significant impact
on the clinical outcome in our patients possibly due to
the limited number of patients included in this cohort.
However, this result could also be justified by the fact
that the most frequent histology in our series was squa-
mous cell carcinoma (76.4%), and, as previously pub-
lished, Id1 expression has no prognostic impact among
patients bearing tumors with this histology [12].
Conclusions
In conclusion, the present study suggests that the tumor
co-expression of Id1 and Id3 can be a powerful prognos-
tic biomarker in a selected subgroup of stage III-N2
NSCLC patients receiving definitive chemoradiotherapy.
Further prospective studies in larger patient cohorts
are warranted to better define the exact prognostic sig-
nificance of the Id1/Id3 co-expression in NSCLC and
whether the isolated expression of one or the other is
sufficient to observe the same effect. A comparison of
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matching metastatic tissues should be also investigated.
At the same time, the subjacent molecular mechanisms
involved, such as the tumor hypoxia, should be pro-
spectively explored, especially in patients treated with
chemoradiotherapy, in whom these proteins might play
a role in the resistance of tumor cells to the different
multimodal therapeutic strategies.
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